What is Avania?
Avania operates as a comprehensive, full-service contract research organization (CRO) specializing in the end-to-end management of clinical trials for medical devices, in-vitro diagnostics (IVDs), and biologics. By providing a customized approach that spans from initial first-in-human studies to post-market surveillance, the company serves as a critical partner for innovators looking to bring complex medical technologies to market. Their market position is defined by a commitment to accelerating the commercialization process while maintaining rigorous standards for patient safety and regulatory compliance across international jurisdictions.
How much funding has Avania raised?
Avania has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Avania
PPP
Public-Private Partnership
What's next for Avania?
With this latest injection of capital, Avania is well-positioned to scale its global infrastructure and enhance its service offerings for device-drug combination products. The strategic focus will likely center on expanding its footprint in key international markets and investing in digital health technologies that streamline clinical data collection. As the medical technology sector faces increasing pressure to deliver faster, more reliable outcomes, Avania's ability to provide seamless support from innovation to commercialization will be a primary driver of its long-term competitive advantage and sustained financial performance.
See full Avania company page
